Case report describes atrial fibrillation ceasing after semaglutide start

The wire

1. 01Semaglutide was started in January 2026 at 0.25mg weekly with escalation; wearable rhythm monitoring since 2023 had documented episodes of 8 to 30 hours, and episodes stopped immediately after initiation with 14kg lost over six months.
2. 02Cardiologists managing obese patients with refractory AF may see this as a signal for cardiometabolic adjuncts to rhythm control.
3. 03It is a single case in European Heart Journal Case Reports; the authors state causality cannot be established and call for prospective studies.

From the source

Cardiometabolic therapy for rhythm control: a case report of refractory atrial fibrillation resolving after initiation of semaglutide for obesity

European heart journal. Case reports · 2026 Oct · Weitkamp FM, Vatic M, von Haehling S et al.